| Symbol | NVCT |
|---|---|
| Name | NUVECTIS PHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1 BRIDGE PLAZA,SUITE 275, FORT LEE, New Jersey, 07024, United States |
| Telephone | +1 201 614-3150 |
| Fax | — |
| — | |
| Website | https://www.nuvectis.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001875558 |
| Description | Nuvectis Pharma Inc is a biopharmaceutical company. Additional info from NASDAQ: |
(99% Neutral) NUVECTIS PHARMA, INC. (NVCT) Announces Business Combination
Read moreNew Form S-3 - Nuvectis Pharma, Inc. <b>Filed:</b> 2026-08-21 <b>AccNo:</b> 0001104659-26-099717 <b>Size:</b> 1 MB
Read moreNuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
Read moreNuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
Read moreCorrection: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Read moreCorrection: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Read moreCiprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Read moreCiprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Read moreMosseri Marlio Charles 🟢 acquired 50.0K shares of Nuvectis Pharma, Inc. (NVCT) at $18.32 Transaction Date: Jun 30, 2026 | Filing ID: 079793
Read moreDirector BENTSUR RON 🟢 acquired 12.5K shares of Nuvectis Pharma, Inc. (NVCT) at $20.00 Transaction Date: Jun 30, 2026 | Filing ID: 079792
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07315113 | Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Sm… | Phase1 | EGFR Mutation Positive Non-small Cell Lung Cancer | Recruiting | 2025-12-18 | 2027-06-01 | ClinicalTrials.gov |
| NCT05873686 | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | Phase1 | Advanced Solid Tumor | Recruiting | 2023-10-26 | 2027-07-01 | ClinicalTrials.gov |
| NCT05226507 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expans… | Phase1 | Advanced Solid Tumor | Terminated | 2021-12-31 | 2025-01-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| NXP800 | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05226507 |
| Osimertinib | Other | Phase PHASE1 | EGFR Mutation Positive Non-small Cell Lung Cancer | RECRUITING | NCT07315113 |
| NXP900 | Other | Phase PHASE1 | EGFR Mutation Positive Non-small Cell Lung Cancer | RECRUITING | NCT07315113 |
| NXP900 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05873686 |
| NXP800 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05226507 |
| Osimertinib | Other | Phase PHASE1 | EGFR Mutation Positive Non-small Cell Lung Cancer | RECRUITING | NCT07315113 |
| NXP900 | Other | Phase PHASE1 | EGFR Mutation Positive Non-small Cell Lung Cancer | RECRUITING | NCT07315113 |
| NXP900 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05873686 |
| Osimertinib | DRUG | Phase PHASE1 | EGFR Mutation Positive Non-small Cell Lung Cancer | RECRUITING | NCT07315113 |
| NXP900 | DRUG | Phase PHASE1 | EGFR Mutation Positive Non-small Cell Lung Cancer | RECRUITING | NCT07315113 |
| NXP800 | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05226507 |